iRadimed (NASDAQ:IRMD) vs. Organigram Global (NASDAQ:OGI) Head to Head Survey

Organigram Global (NASDAQ:OGI) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Organigram Global and iRadimed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$309.18 million	0.43	-$17.70 million	$0.46	2.06
iRadimed	$86.34 million	12.89	$22.48 million	$1.79	48.61

iRadimed has lower revenue, but higher earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Organigram Global and iRadimed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
iRadimed	0	3	2	1	2.67

iRadimed has a consensus target price of $120.00, suggesting a potential upside of 37.91%. Given iRadimed’s higher probable upside, analysts clearly believe iRadimed is more favorable than Organigram Global.

Insider & Institutional Ownership

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Organigram Global has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Organigram Global and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
iRadimed	26.70%	23.45%	20.36%

Summary

iRadimed beats Organigram Global on 10 of the 13 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.